Brent Moody, MD: Assessing the Prognostic Significance of the 31-gene Expression Profile Test

Dr. Moody discusses a poster presented at the 2025 Fall Clinical Dermatology Conference that evaluated the 31-GEP test across all melanoma subtypes.

MORE EXPERT PERSPECTIVES IN MELANOMA:

Jason Rizzo, MD, PhD: Evaluating Melanoma-specific Survival Stratification and Survival Benefit of Gene Testing in Patients with Melanoma

Learn how 31-GEP testing may help stratify melanoma-specific survival risk and support more personalized care for patients with melanoma.

Jason Rizzo, MD: Utility of Gene Expression Profile Testing for Prognosis in Cutaneous Melanoma

Abel Jarell, MD, FAAD: Identifying the Risk of Central Nervous System Metastasis Using the 31-Gene Expression Profile Test

Hadas Skupsky, MD, FAAD: Pigmented Lesion Management for the Dermatologist

Dr. Hadas Skupsky discusses how ancillary testing can help dermatologists guide clinical decision-making for patients with atypical pigmented lesions.
Linkedin Instagram Youtube Spotify Facebook X-twitter Threads

©2026 Oncology Matrix. All Rights Reserved.